Evaluating of Physiological Chemical Levels in Blood to Assess the Risk of Morbidity and Mortality of Ischemic Cardiovascular Disease

Junyan Teng $^{1,2}$, Yanping Wei $^3$, Fengming Su $^4$, Zhiping Guo $^2$ and Jing-Quan Zhong $^{1,*}$

$^1$ The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China; E-Mail: junyanteng@hotmail.com

$^2$ Luoyang Orthopedic-Traumatological Hospital, Zhengzhou 450000, Henan, China; E-Mail: guozhiping74@hotmail.com

$^3$ Henan Province People’s Hospital, Zhengzhou 450003, Henan, China; E-Mail: wei_yp1234@163.com

$^4$ Emergency Medical Rescue Center of Zhengzhou City, Zhengzhou 450000, Henan, China; E-Mail: zz120su@163.com

* Author to whom correspondence should be addressed; E-Mail: gilman_zhong@hotmail.com; Tel.: +86-185-6008-6597; Fax: +86-0531-8692-7544.

Academic Editor: Paul B. Tchounwou

Received: 12 July 2015 / Accepted: 7 September 2015 / Published: 14 September 2015

Abstract: In this study, a multiple linear regression model to evaluate the risk of morbidity and mortality of ischemic cardiovascular disease is demonstrated. In this model, predictor variables are selected from physiological chemicals in a blood test of the subjects. Meanwhile, the calculated risk score is selected as a response variable. Four major latent variables including hepatic, nephric, metabolic, and BMI (Body Mass Index) are revealed by performing statistical and principal component analysis for the collected survey data. The analyzed result also shows that the cardiac disorder is correlated with symptoms of abnormal BMI, hepatic disorder, nephric disorder, and metabolic disorder. Thus, the risk of morbidity and mortality of ischemic cardiovascular disease can be assessed from the proposed multiple regression model.
1. Introduction

Cardiovascular disease is one of the leading causes of death [1]. From an epidemiology point of view, if some of the levels of physiological chemicals (markers) in blood could reveal the possibility of cardiac disorder, the death rate of Ischemic Cardiovascular Disease (ICVD) should be reduced. The laboratory blood test is a tool helpful in evaluating the health status of an individual [2]. For instance, the level of lactate dehydrogenase (LDH) in blood rises when the patient is suffering from myocardial infarction, pulmonary embolism, hepatic disorder, and muscle disorder [3]. Blood creatinine kinase (CK) is a cardiac predictive marker. Creatine Kinase (CK) is the acute cardiac injury flag because of its excellent specificity. The ratio of CK-MB to total CK, especially when the CK-MB rises, is a sensitive indicator of myocardial injury [4,5].

Previous reports pointed out that a 1 mmol/L increase in the plasma triglyceride level might cause a two-fold increase in the risk of cardiovascular disease for the male gender [6]. However, even though blood triglycerides (TG) are an important factor that affect the risk of cardiac disorder, no direct evidences shows that the increasing triglyceride level is an independent predictor for cardiovascular disorder [7].

Serum alkaline phosphatase (ALP) plays a physiological role in affecting the risk of cardiovascular disorder [8,9]. ALP subjects physiological variations are closely associated with age based upon the physiological hormonal changes. As found in human blood of hepatic disease without jaundice, ALP elevation alerts the risk of cardiac disorder. We are not surprised that the presence of the predictive marker of hepatic disorder is highly correlated with cardiovascular disease [10].

Alanine aminotransferase (ALT), also called SGPT (serum glutamic-pyruvic transaminase) or GPT, is an enzyme indicator in blood. The level of ALT is generally less than 30–40 U/L. ALT rises to indicate the hepatic damage. AST (aspartate aminotransferase) is called SGOT (serum glutamic-oxalocetic transaminase) or GOT. The blood test level of AST is generally less than 40–50 U/L. ALT and AST are the ones used to test liver function; however, in the heart, tissue damage can also result in increasing blood ALT [11].

With respect to the ALT, AST is more non-specific. Increased AST is an important indicator of hepatic injury [12]. Physicians have been interested in if GPT or GOT affects the cardiac disorder for decades [13]. In China, based on 17 years of follow-up observation and using of the Cox proportional hazard model to evaluate the risk of morbidity and mortality of cardiac disorder, risk score (RS) calculation procedures was reported by Wu et al. [14]. However, we concern about if the ICVD can be found in a head of time via the precursors in the blood. Through the RS in terms of the markers in blood, we might be able to assess and alert the clinicians to the risk of ICVD in the patients [15].

In RS calculation procedures, the age, systolic blood pressure (SBP), body mass index (BMI), serum total cholesterol (TC), diabetes (GLU), and smoking history were the six factors collected as independent (predictor) variables. To explain the features of RS, we considered a 50-year-old male subject with a
systolic blood pressure of 150/90 mmHg, BMI of 25, serum total cholesterol of 5.46 mmol/L, and positive smoking history but no diabetes as an example to calculate the RS for assessing the risk of morbidity and mortality of ICVD. Following the standardizations by Wu et al. [14], parameter X1 represents the age effect; because the subject is 50 years old, X1 is assessed at three points for estimating the risk of morbidity and mortality of ICVD. Parameter X2 represents the blood pressure effect, and the systolic blood pressure of the subject is 150 mmHg, so X2 is assessed at two points for the risk estimation. Parameter X3 represents the BMI effect and subject has a BMI of 25, so X3 is assessed at only one point toward the risk of morbidity and mortality related to ICVD. X4 represents the total cholesterol (TC) effect and the level in the blood of the subject is 5.46 mmol/L, so X4 is assessed to be one point. X5 represents the subject’s lifestyle; smoking is assessed at two points (no smoking is assigned zero points). X6 represents the subject’s lack of diabetes, and it is assessed at zero points for the risk (with diabetes assessed as one point). Summing the points from X1 to X6, 3 + 2 + 1 + 1 + 2 + 0 = 9, we can get the risk score of nine points, which means the subject has a low risk level of ICVD under the criteria of the safe level (RS < 8), low risk level (8 ≤ RS ≤ 10), and high risk level (RS > 10). Equation (1) demonstrates the calculation of RS proposed by Wu et al. [14]

\[ RS = X_1 + X_2 + X_3 + X_4 + X_5 + X_6 \] (1)

In this study, collecting enough subjects from the general population in Henan, China, we want to calculate RS for the subjects. Meanwhile, we assume that the RS is correlated with the selected predictors in blood so that we may find the significance of the markers in the blood to assess the risk of morbidity and mortality of ICVD statistically. By using principal component analysis (PCA), four principal predictors were revealed, and they are hepatic-, nephritic-, metabolic-, and BMI-related markers. The hepatic (H)-related markers comprise ALT, GOT, and GGT. The metabolic (M)-related markers include alkaline phosphatase (ALP), low-density (LDL) and high-density cholesterol (HDL), and triglycerides (TG). The nephritic (N)-related markers comprise creatine (CR) and uric acid (UA). Originally, with BMI (B), 10 predictors were selected for a linear regression to predict a response variable RS. The significance of those factors’ influence on the risk of morbidity and mortality of ICVD were reviewed. Meanwhile, a new predictive model for RS in terms of H, M, N, and B to assess the risk of morbidity and mortality of ICVD were proposed and analyzed.

2. Methods

Design and Sample

Since three million people die with ICVD in China each year, the research of the associations on the morbidity and mortality of ICVD has become an important concern [14]. There were 2400 cases where the subjects, male or female, ranging 35 to 59 years old, were assigned randomly to answer specific medical questionnaires as well as to do lab blood tests. The aim of this study is to specify the degree of significance of some specific hepatic enzymes, serum cholesterol, metabolic physiological chemicals, and TG level effects presented by RS in the blood to evaluate the risk of morbidity and mortality of ICVD. In previous research, six predictor variables included age, systolic blood pressure (SBP), body mass index (BMI), serum total cholesterol (TC), with or without diabetes (GLU), and smoking history, and these were well defined to calculate RS. In this study, we stratified the RS into three levels
comprising the safe level (RS < 8), the low risk level (8 ≤ RS ≤ 10), and the high risk level (RS > 10). The former research revealed that RS for evaluating the risk of the morbidity and mortality of ICVD is significantly associated with gender, age, blood pressure, body mass index, smoking, and diabetes mellitus. However, the association of the physiological chemicals in blood with response variable RS to assess the risk of morbidity and mortality of ICVD was not involved in the previous study [13–15].

In order to get the response variable RS in terms of the predictor variables of BMI, LDL, HDL, GOT, GGT, ALT, ALP, TG, CK, and uric acid (UA) for assessing the risk of morbidity and mortality of ICVD, we used multiple regression procedures to create a regression model to calculate the RS with those predictors. We attempt to understand the physiological chemical levels in the blood comprising ALT, GOT and GGT, TG, low-density cholesterol, high-density cholesterol, creatinine, and ALP correlated with the risk of morbidity and mortality related to ICVD.

As we planned, 2400 subjects in Henan Provincial People’s Hospital, aged from 35 years old to 59 years old, were collected from physical health lab. Of the 2400 subjects, were corresponded with. The selected effective rate was 92.13%. Survey information included demographic data (gender, age, nature, and position of units), lifestyle (smoking and drinking), medical history (history of diabetes mellitus, coronary artery disease, and cerebral apoplexy), and the record of physical examination (systolic blood pressure, total cholesterol, and body mass index), etc. Blood lipid and blood glucose levels were all checked using Switzerland Roche reagents (Roche Diagnostics GmbH., SandhoferStrasse 116, 68,305 Mannheim, Germany) for calculating RS. Meanwhile, we selected and measured the levels of BMI, ALT, GOT, GGT, TG, LDL, HDL, CK, UA, and ALP from the blood test to associate with RS by multiple-variable regression procedures as well as principal component analysis.

3. Statistical Analysis and Multiple-Variable Regression Procedures

From the data of the blood test, we realized that none of the physiological chemicals could be an independent affecting factor for assessing the risk of cardiac disorder. We realized that, for male gender, the coefficients of correlation between RS and each of the two variables could not be in linearity because the p-value for testing was not significant (p > 0.001). For female subjects (not shown), the significance of the testing should not be able to reject the null hypothesis (no linear correlation being found), which means the coefficient of the correlation is close to zero. Thus, we decided to stratify the RS and use principal component analysis (PCA) to find the significance of the predictor variables and then perform a multiple-variable regression analysis to calculate a response variable RS in terms of predictor variables for assessing the risk of morbidity and mortality of ICVD for the subjects without gender classification.

By using principal component analysis, we obtained four principal components comprised of H (Hepatic), N (Nephritic), M (Metabolic), and B (BMI). Using a step-by-step approach, we first correlated nine different observation variables including hepatic enzymes ALT, GOT and GGT, TG, low-density cholesterol, high-density cholesterol, CK, UA, and ALP. Then, we performed statistical analysis to get the weighting coefficient for each principal component associated with the response variable (RS) to assess the risk of morbidity and mortality of ICVD. Finally, a multiple-variable regression analysis was used to reveal the rank of significance of the observations at different stratification levels of RS [16] and, then, we completed a model with a good coefficient of the determination.
4. Results

In Table 1, it shows the Pearson’s correlation coefficients and the p-value for testing the significance of the selected physiological chemicals (marks) in blood.

| Markers | Level |
|---------------------------------|-------|
| BMI | <18.5 or >25 |
| HDL | >1.8 mmol/L |
| LDL | >3.36 mmol/L |
| TG | >2.25 mmole/L |
| CK | male > 104 μmol/L |
| | female > 84 μmol/L |
| Uric Acid | male > 416 μmol/L |
| | female > 257 μmol/L |
| ALP | >129 U/L |
| GOT | >33 U/L |
| GGT | >40 U/L |
| ALT | >81 U/L |

The RS was stratified into three levels as no risk (RS = 1), low risk (RS = 2), and high risk (RS = 3). Performing the PCA and multiple regression analysis, we reduced the predictor variables to get four mixed PCA predictor variables. Based upon our analysis, at different levels of stratified RS, the form of the proposed multiple-variable regression model is presented as Equation (2).
In Table 3, calculated β coefficients correlated to the predictor variables for the response of RS are presented. Predictor variables include ASP, ALT, GGT, GOT, TG, CK, UA, LDL, HDL, and BMI, and we used them to calculate the response RS and construct a multiple regression model with the linear combination of those predictor variables. Here we named it RM1.

\[
RS = \beta_0 + \beta_1H + \beta_2N + \beta_3M + \beta_4B
\]  

(2)

Table 3. RM1 multiple-variable regression model of the selected markers in blood for the clinical population collected in Henan Province, China.

| RM1: RS | Coefficients without Standardization | Standardized Coefficient | t | Significance p-Value | 95.0% Confidence Interval of β |
|--------|--------------------------------------|--------------------------|---|---------------------|-----------------------------|
|        | Estimation of β | Standard Error | Beta Distribution | | Lower Bound | Upper Bound |
| Constant | -12.714 | 0.749 | -16.973 | 0.000 | -14.183 | -11.245 |
| BMI | 0.409 | 0.022 | 0.389 | 18.980 | 0.000 | 0.366 | 0.451 |
| HDL | 0.585 | 0.232 | 0.049 | 2.519 | 0.012 | 0.130 | 1.041 |
| LDL | 0.801 | 0.086 | 0.173 | 9.310 | 0.000 | 0.632 | 0.970 |
| TG | 0.227 | 0.044 | 0.100 | 5.134 | 0.000 | 0.140 | 0.314 |
| CK | 0.020 | 0.005 | 0.082 | 4.184 | 0.000 | 0.011 | 0.030 |
| UA | 0.248 | 0.055 | 0.085 | 4.488 | 0.000 | 0.140 | 0.356 |
| ALP | 0.011 | 0.003 | 0.070 | 3.717 | 0.000 | 0.005 | 0.016 |
| ALT | -0.014 | 0.006 | -0.081 | -2.429 | 0.015 | -0.025 | -0.003 |
| GOT | 0.013 | 0.011 | 0.039 | 1.215 | 0.225 | -0.008 | 0.034 |
| GGT | 0.011 | 0.002 | 0.113 | 5.317 | 0.000 | 0.007 | 0.015 |

The multiple-regression model RM1 presented in Table 3 is presented in Equation (3)

\[
RS = -12.714 + 0.409 \times BMI + 0.585 \times HDL + 0.801 \times LDL + 0.227 \times TG + 0.020 \times CR + 0.248 \times UA + 0.011 \times ALP - 0.014 \times ALT + 0.013 \times GOT + 0.011 \times GGT
\]  

(3)

In Table 4 and from Equation (4) to Equation (7), we show the impact weighting coefficients of the principal components analysis, which were proceeded by using the software IBM SPSS 22. The presented impact weighting coefficient for each component was calculated at a specific risk value where GOT, GGT, CR, UA, TG, and CK are the levels of the selected markers in the blood collected from the subjects.

\[
H = H_{11} \times GOT + H_{12} \times GGT
\]  

(4)

where \(H_{11} = 0.808\) and \(H_{12} = 0.750\) are the impact weighting coefficients

\[
N = N_{11} \times CR + N_{12} \times UA
\]  

(5)

where \(N_{11} = 0.737\) and \(N_{12} = 0.598\) are the impact weighting coefficients

\[
M = M_{11} \times TG + M_{12} \times CK
\]  

(6)

where \(M_{11} = 0.737\) and \(M_{12} = 0.598\) are the impact weighting coefficients
BMI = Body weight (Kg)/Square of the Height of the body (m²).  (7)

These four integrated factors, H, N, M, and B, affect the risk of morbidity and mortality related to ICVD. By using them, we proposed a multiple-variable regression model of RM2.

**Table 4.** Impact weighting coefficients of the principal components presented by the selected physiological chemicals (markers) in blood for a specific RS value.

|        | H     | B     | N     | M     |
|--------|-------|-------|-------|-------|
| BMI    | 0.182 | 0.744 | −0.009| −0.003|
| HDL    | 0.494 | −0.196| −0.158| −0.302|
| LDL    | 0.329 | 0.482 | 0.141 | −0.520|
| TG     | 0.227 | 0.544 | −0.168| 0.221 |
| CK     | −0.216| 0.116 | 0.737 | 0.358 |
| UA     | −0.289| 0.369 | 0.598 | −0.224|
| ALP    | 0.193 | 0.480 | −0.277| −0.143|
| ALT    | 0.746 | −0.109| 0.475 | 0.017 |
| GOT    | 0.808 | −0.325| 0.343 | −0.089|
| GGT    | 0.750 | −0.031| −0.198| 0.176 |

Table 5 shows the β coefficients correlated to the predictor variables for the response RS presented by the linear combination of H, B, N, and M, the four principal components. From the analysis, the sort order of the significance of the principal components affecting the risk score is H > B > N > M when RS is equal to 3 (RS = 3). Meanwhile, H > M > N > B is the order when RS is equal to 2 (RS = 2). Equation (8) is the multiple-variable regression model of RM2. Based upon the analysis results, we realized that the significance of the components is varied via the level of risk score to affect the assessment of the risk of ICVD.

\[
RS = 11.417 + 0.222 \times H - 0.101 \times N + 1.914 \times M + 0.425 \times B
\]  (8)

**Table 5.** RM2 multiple regression model coefficients of the principal components of the correlation matrix of the selected physiological chemicals in the blood of subjects.

| RM2: RS | Coefficients without Standardization | Standardized Coefficient | t | Significance p-Value | 95.0% Confidence Interval of β |
|---------|-------------------------------------|--------------------------|---|----------------------|--------------------------------|
|         | Estimation of β | Standard Error | Beta Distribution |        |                    | Lower Bound | Upper Bound |
| Constant | 11.417 | 0.062 | -- | 185.305 | 0.000 | 11.296 | 11.538 |
| Hepatic | 0.222 | 0.041 | 0.042 | 5.398 | 0.000 | 0.141 | 0.303 |
| BMI     | 0.425 | 0.030 | 0.123 | 14.168 | 0.000 | 0.366 | 0.484 |
| Nephric | −0.101 | 0.029 | −0.031 | −3.494 | 0.000 | −0.157 | −0.044 |
| Metabolic | 1.914 | 0.020 | 0.886 | 96.382 | 0.000 | 1.875 | 1.953 |

Comparing the two multiple-variable regression models RM1 and RM2, we realized that the determination coefficients increased from 0.336 to 0.878 after principal component analysis (PCA) proceeded. With an orthogonal transformation converting a set of predictor variables to a projected set, a set of weighting numbers for uncorrelated variables can be assigned to linearize correlations for predictor variables and the response variable. Table 5 also shows the weighting numbers of the four major
components H, N, M, and B that contributed to the response variable. Comparing Equation (3) and Equation (8), we realized that the predictor variables are reduced to four major components by the principal component analysis. To calculate RS in terms of H, N, M, and B, it would be the same as calculating RS in terms of X1, X2, X3, X4, X5, and X6. Multiple-variable regression proceeds with different predictors, and both H, N, M, and B, and X1, X2, X3, X4, X5, and X6 should be at the same level of RS at a reasonable determination coefficient.

Table 6 shows the determination coefficients of the models RM1 and RM2. Comparatively, we realized that in the RM2 model, the Durbin-Watson test is larger than 1.5 (criteria value) and the coefficient of the determination (CD) is 0.8 and the correlation coefficient reaches 0.937 (higher is better), indicating a good model fit to the statistic criteria to assess the risk of morbidity and mortality of ICVD presented by the risk score.

Table 6. Coefficients of determination (CD).

|   | R     | R Square (CD) | Standard Error of the Estimation | Durbin-Watson Test |
|---|-------|---------------|----------------------------------|--------------------|
| RM1 | 0.580 | 0.336         | 2.726                            | 1.359              |
| RM2 | 0.937 | 0.878         | 1.169                            | 1.764              |

5. Discussions

Based upon causality theory, the independent predictor is an only factor that can cause a specific effect. In this study, no single predictor was revealed to affect the risk of morbidity and mortality of ICVD alone. Thus, we conclude that none of the markers we discussed can be an independent predictor. A multiple linear regression model is thus proposed to present the scale of contribution of every marker that contributes to a risk score. We selected several markers to be the predictor variables, including ALT, ASP, GOT, GGT, LDL, CK, TG, UA, and BMI. In this study, we realized all of our selected markers are responsible for affecting the risk of morbidity and mortality related to ICVD.

Typical methods to estimate risks of cardiovascular disease includes the Cardiovascular Disease Risk Calculator proposed by Kaplan and Meier [17], Cox’s proportional hazards model [18], Canadian [19] and American Heart Association (AHA)[20] guidelines, etc. However, those methods are for clinicians who consider risk factor burden in the patients’ lifetime a risk for cardiovascular disease. In our study, we proposed an easy and accurate multiple-variable regression model for all populations that do and do not have specific cardiovascular disease symptoms. With the data of regular lab blood tests and our proposed model, people can get the risk score to assess their risk for ICVD. It will be helpful for the populations who want to find out their risk of morbidity and mortality of ICVD when they do regular health exams.

Basically, the existing models referred to in the references [17–20] are not really applicable for causality analysis in etiology, which means those existing models and knowledge are not able to explain which factors affect the risk of morbidity and mortality of ICVD. In this study, we present our model from an epidemiological point of view, ending with integrated hepatic, nephric, metabolic, and BMI-related predictors which may correlate to the etiological point of view to explain the factors that affect the risk of morbidity and mortality related to ICVD.

Based upon the ICVD risk score computing procedures proposed by Wu et al. in 2003 [14], the risk factors comprise age, SBP, BMI, serum total cholesterol (TC), presence of diabetes (GLU), and smoking
history. Then, we stratified the RS into several levels to show the different significance of the impact of the markers for evaluating the risk of morbidity and mortality of ICVD. The principal component analysis (PCA) of the correlation matrix of selected markers from the subjects revealed four major factors which are hepatic (H), metabolic (M), nephritic (N), and BMI (B). The rank order of the major components presents the significance level of the impact of those factors. H > B > N > M is the order when the RS is equal to 3 (RS = 3), but when the RS equals 2, the significance level of the impact that affects evaluating the risk of ICVD is changed to H > M > N > B for the subjects. Furthermore, GOT, GGT, CK, and TG were realized to be the top four important markers in the blood that affect the risk of morbidity and mortality related to ICVD.

Statistically, the proposed multiple-variable regression model for calculating RS in terms of the four major principal components H, M, N, and B has shown the linear combinations of H, M, N, and B with an acceptable coefficient of determination as well as the weighting coefficients. From the epidemiological point of view, our study is to note that clinicians should remind their patients to pay full attention to their lab blood test results. Any high hepatic, nephritic, or metabolic levels and quick BMI changes mean the body is providing a warning of the risk of morbidity and mortality related to ICVD.

6. Conclusions

An independent predictor means that only one causal factor exists to initiate a specific effect [21]. In this study, no single independent predictor was revealed, which means none of the markers we discussed can be an independent predictor that affects the risk of ICVD. A linear multiple-variable regression model is thus proposed to present the substantial function of each marker that we discussed. The calculated weighting coefficients in the model can present the probability distribution to the calculated RS proposed by Wu et al. [14], which is also correlated with Cox’s proportional hazards model to assess the risk of morbidity and mortality of ICVD. By using PCA for the data analysis, it is revealed that the H, N, M, and B impact the RS to assess the risk of morbidity and mortality of ICVD for the clinical population selected. Statistically, good CD, R values, and a Durbin-Watson Test can guarantee a good model for the selected population. Meanwhile, RS is also recognized as a good index to assess the risk of morbidity and mortality of ICVD. Therefore, we conclude that our proposed model is valuable for using physiological chemicals (markers) in the blood to assess the risk of morbidity and mortality of ICVD.

Acknowledgments

This study was sponsored by the Natural Science Foundation of China (81270238), the Scientific Research Foundation for the Doctoral Degree, State Education Ministry of China (20100131110059), the Scientific Development Plan of Shandong Province of China (2012G0021850) and the Soft science project of Henan Province of China (122400450432).

Author Contributions

Junyan Teng had the original idea for the study, performed the statistical analysis and English writing, Yanping Wei carried out the design, Fengming Su did the survey, Zhiping Guo did the references collection and Jing-Quan Zhong did the organization of the composition for the manuscript.
Conflicts of Interest

The authors declare no conflict of interest.

References

1. Celermajer, D.S.; Chow, C.K.; Marijon, E.; Anstey, N.M.; Woo, K.S. Cardiovascular disease in the developing world: Prevalences, patterns, and the potential of early disease detection. J. Am. Coll. Cardiol. 2012, 60, 1207–1216.

2. Graham Basten. Introduction to Clinical Biochemistry: Interpreting Blood Results, 2010. Available online: http://web.mef.hr/web/images/pdf/i_clin_bio.pdf (accessed on 11 September 2015).

3. Wachter, R.M. Clinical Applications of LDH Isoenzyme Determinations. PhD. Thesis, University of Nebraska, Lincoln, NE, USA, 1969.

4. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, doi:10.1371/journal.pmed.0030442.

5. Januzzi, J.L.; Kent Lewandrowski, T.E.; MacGillivray, J.B.; Newell, S.K.; Servoss, S.J.; Lee-Lewandrowski, E. A comparison of cardiac troponin T and Creatine Kinase-MB for patient evaluation after cardiac surgery. J. Am. Coll. Cardiol. 2002, 39, 1518–1523.

6. Sarwar, N.; Danesh, J.; Eiriksdottir, G.; Sigurdsson, G.; Wareham, N.; Bingham, S.; Matthijs Boekholdt, S.; Khaw, K.-T.; Gudnason, V. Triglycerides and the risk of coronary heart disease 10158 incident cases among 262525 participants in 29 western prospective studies. Circulation 2007, 115, 450–458.

7. Tirosh, A.; Shai, I.; Bitzur, R.; Kochba, I.; Tekes-Manova, D.; Israeli, E.; Shochat, T.; Rudich, A. Changes in triglyceride levels over time and risk of type 2 diabetes in young men. Diabetes Care 2008, 31, 2032–2037.

8. Webber, M.; Krishnan, A.; Thomas, N.G.; Cheung, B.M.Y. Association between serum alkaline phosphatase and c-reactive protein in the united states national health and nutrition examination survey 2005–2006. Clin. Chem. Lab. Med. 2010, 48, 167–173.

9. Ali, A.T.; Penny, C.B.; Paiker, J.E.; van Niekerk, C.; Smit, A.; Ferris, W.F.; Crowther, N.J. Alkaline phosphatase is involved in the control of adipogenesis in the murine preadipocyte cell line, 3T3-L1. Clin. Chim. Acta 2005, 354, 101–109.

10. Fouad, Y.M.; Yehia, R. Hepato-cardiac disorders. World J. Hepatol. 2014, 6, 41–54.

11. Jiang, S.Y.; Jiang, D.L.; Tao, Y. Role of γ-Glutamyltransferase in cardiovascular diseases. Exp. Cardiol. Rev. 2013, 18, 53–56.

12. Kim, W.R.; Flamm, S.L.; Biscceglie A.M.D.; Bodenheimer, H.C. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008, 47, 1363–1370.

13. Huang, X.J.; Choi, Y.K.; Im, H.S.; Yarimaga, O.; Yoon, E.; Kim, H.S. Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) detection techniques. Sensor 2006, 6, 756–782.

14. Wu, Y.F. A study on evaluation of the risk of ischemic cardiovascular diseases in Chinese and the development of simplified tools for the evaluation. Chin. J. Cardiol. 2003, 31, 893–900.

15. Reddy, K.S.; Yusuf, S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998, 97, 596–601.
16. Mendenhall, W.; Beaver, R.J.; Beaver, B.M. *Introduction to Probability and Statistics*, 12th ed.; Thomson Brooks: New York, NY, USA, 2006.
17. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* 1958, 53, 457–481.
18. Cox, D.R. Regression models and life-tables (with discussions). *J. R. Stat. Soc. B* 1972, 34, 187–220.
19. Anderson, T.J.; Grégoire, J.; Hegele, R.A.; Couture, P.; Mancini, G.B.J.; McPherson, R.; Francis, G.A.; Poirier, P.; Lau, D.C.; Grover, S.; *et al.* 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can. J. Cardiol.* 2013, 29, 151–167.
20. Mosca, L.; Appel, L.J.; Benjamin, E.J.; Berra, K.; Chandra-Strobos, N.; Fabunmi, R.P.; Grady, D.; Haan, C.K.; Hayes, S.N.; Judelson, D.R.; *et al.* Evidence-based guidelines for cardiovascular disease prevention in women. *Circulation* 2004, 109, 672–693.
21. Beiser, A.D.; Agostino, R.B.; Seshadri, S.; Sullivan, L.M.; Wotlf, P.A. Computing estimates of incidence including lifetime risk. *Stat. Med.* 2002, 19, 1495–1522.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).